SLC5A2 and myocardial infarction: A multi-database retrospective cohort study also identified that SGLT2 inhibitors were related to a reduced risk of HF (0.43), cardiovascular death (0.60), MACE (HR = 0.76) and myocardial infarction (0.82) compared with DPP-4 inhibitors.